Multiplex Assays Market Competition, Size, Demand and Future Trends 2030

Multiplex Assays Market Size, Share & Trends Analysis By Product & Service, By Type, By Technology, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Published: Feb-2022	Report ID: BIOT2202	Pages: 1 - 243	Formats^*:
Category : Biotechnology

Global Multiplex Assays Market Overview:

According to SPER Market Research, the Multiplex Assays Market estimated to reach USD 5.6 billion by 2030 with a CAGR of 7.2%. The rising prevalence of chronic disorders require advanced diagnostic tools and testing methods for early detection and better treatment.

Impact of COVID-19 on the Multiple Assays Market

Multiplex assay market has grown significantly during the COVID-19 pandemic. Multiplex assays have been utilized for the diagnosis of SARS-CoV-2. The regulatory approvals were also relaxed to fasten the manufacturing and availability in the market to meet elevated demand. Temporary operational challenges were observed due to lockdowns. Overall, a positive impact is being observed with relaxation in travelling restrictions and rising demand for diagnosis purpose.

Scope of the report:

Report Metric	Details
Market size available for years	2019-2030
Base year considered	2021
Forecast period	2022-2030
Segments covered	By Product & Service, By Type, By Technology, By Application, By End User
Geographies covered	North America, Europe, APAC, Latin America and the Middle East & Africa
Companies Covered	Abcam Plc, Agilent Technologies, Inc., Antigenix America, Inc., AYOXXA Biosystems GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Boster Biological Technology, Cayman Chemical Company, DiaSorin S.p.A., Enzo Life Sciences, Inc., Illumina, Inc, Luminex Corporation, Merck KGaA, Meso Scale Diagnostics Olink, PerkinElmer, Inc., Promega Corporation, Qiagen N.V., Quanterix, Randox Laboratories, Seegene, Shimadzu Biotech, Siemens Healthineers, Thermo Fisher Scientific Inc.

Driver: Rising use of multiplex assays

The use of multiplex assays is rising due to the increasing prevalence of chronic diseases and advantages offered by multiplex assays over singleplex assays. Multiplex assays provide faster delivery of diagnostic results and detection at lower concentration of reagents and analytes as compared to traditional and singleplex assays.

Restraint: High equipment cost and stringent regulatory framework

The equipment utilized in the manufacturing of multiplex assays are expensive which creates challenges to provide multiplex assay testing at an affordable cost. Additionally, the standards for Quality control are more stringent for multiplex assays in comparison to singleplex assays.

Opportunity: Rising validation of biomarkers

The validation of biomarkers is increasing in protein and molecular diagnostics. The technological advancements in multiplex assay testing instruments will increase efficiency and accuracy of the results which will create growth opportunities for multiplex assay market in the diagnosis of neurodegenerative disorders, cancer and autoimmune diseases.

Challenge: Lack of skilled technicians

There is a lack of skilled technicians who can handle multiplex assay instruments. This can pose a challenge to the growth of this market.

Multiple Assays Market Segmentation:

By Product & Service: Based on product and service, market has been segmented into Consumables, Instruments, Software & Service

By Type: Based on type, market has been segmented into Protein Multiplex Assays (Planar Protein Assays, Bead-Based Protein Assays, Other Protein Assays), Nucleic Acid Multiplex Assays (Planar Nucleic Acid Assays, Bead-Based Nucleic Acid Assays, Other Nucleic Acid Assays), Cell-Based Multiplex Assays

By Technology: Based on technology, market has been segmented into Flow Cytometry, Fluorescence Detection, Luminescence, Multiplex Real-Time PCR, Other Technologies

By Application: Based on application, market has been segmented into Research & Development (Drug Discovery & Development, Biomarker Discovery & Validation), Clinical Diagnostics (Infectious Diseases, Cancer, Cardiovascular Diseases, Autoimmune Diseases, Nervous System Disorders, Metabolism & Endocrinology Disorders, Other Diseases

By End User: Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes, Reference Laboratories, Other End Users Pharmaceutical & biotechnology companies have the largest share of this market by end user due to rising adoption of multiplex assay testing in drug development process and rising focus on monoclonal antibodies & biosimilar products.

By Region: North America owns the largest share of this market due to factors such as presence of strong pharmaceutical industry, high Research and Development investment, technological advancement and growing biotechnology companies.

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Dynamics

4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges

4.3. COVID-19 Impact of the Multiplex Assays Market
4.4. Market Trends

5. Global Multiplex Assays Market, By Product & Service, 2019-2030 (USD Million)

5.1. Consumables
5.2. Instruments
5.3. Software and Service

6. Global Multiplex Assays Market, By Type, 2019-2030 (USD Million)

6.1. Protein Multiplex Assays

6.1.1. Planar Protein Assays
6.1.2. Bead-Based Protein Assays
6.1.3. Other Protein Assays

6.2. Nucleic Acid Multiplex Assays

6.2.1. Planar Nucleic Acid Assays
6.2.2. Bead-Based Nucleic Acid Assays
6.2.3. Other Nucleic Acid Assays

6.3. Cell-Based Multiplex Assays

7. Global Multiplex Assays Market, By Technology, 2019-2030 (USD Million)

7.1. Flow Cytometry
7.2. Fluorescence Detection
7.3. Luminescence
7.4. Multiplex Real-Time PCR
7.5. Other Technologies

8. Global Multiplex Assays Market, By Application, 2019-2030 (USD Million)

8.1. Research & Development

8.1.1. Drug Discovery & Development
8.1.2. Biomarker Discovery & Validation

8.2. Clinical Diagnostics

8.2.1. Infectious Diseases
8.2.2. Cancer
8.2.3. Cardiovascular Diseases
8.2.4. Autoimmune Diseases
8.2.5. Nervous System Disorders
8.2.6. Metabolism & Endocrinology Disorders
8.2.7. Other Diseases

9. Global Multiplex Assays Market, By End User, 2019-2030 (USD Million)

9.1. Pharmaceutical & Biotechnology Companies
9.2. Hospitals & Research Institutes
9.3. Reference Laboratories
9.4. Other End Users

10. Global Multiplex Assays Market, By Geography, 2019-2030 (USD Million)

10.1. North America

10.1.1. US
10.1.2. Canada

10.2. Europe

10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe

10.3. Asia-Pacific

10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Rest of Asia-Pacific

10.4. Rest of the World

10.4.1. Latin America
10.4.2. Middle East & Africa

11. Competitive Landscape

11.1. Introduction
11.2. Market Share Analysis, By Key Players
11.3. Competitive Scenario
11.3.1. Product Launches
11.3.2. Partnerships, Collaborations and Agreements
11.3.3. Acquisitions
11.3.4. Expansions
11.3.5. Other Developments

12. Company Profiles

12.1. Abcam Plc
12.2. Agilent Technologies, Inc.
12.3. Antigenix America, Inc.
12.4. AYOXXA Biosystems GmbH
12.5. Becton, Dickinson and Company
12.6. Bio-Rad Laboratories, Inc.
12.7. Bio-Techne Corporation
12.8. Boster Biological Technology
12.9. Cayman Chemical Company
12.10. DiaSorin S.p.A.
12.11. Enzo Life Sciences, Inc.
12.12. Illumina, Inc
12.13. Luminex Corporation
12.14. Merck KGaA
12.15. Meso Scale Diagnostics
12.16. Olink
12.17. PerkinElmer, Inc.
12.18. Promega Corporation
12.19. Qiagen N.V.
12.20. Quanterix
12.21. Randox Laboratories
12.22. Seegene
12.23. Shimadzu Biotech
12.24. Siemens Healthineers
12.25. Thermo Fisher Scientific Inc.

13. Appendix

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1